Immunotherapy Shakes Up GastricGEJ Cancer Space Alongside Angiogenic Cytotoxic Agents

Immunotherapy Shakes Up Gastric/GEJ Cancer Space, Alongside Angiogenic, Cytotoxic Agents

J. Stuart Salmon, MD, highlights first-, second-, and third-line treatment options for patients with gastric and gastroesophageal cancer following recent clinical trial findings and regulatory approvals.

More From BioPortfolio on "Immunotherapy Shakes Up Gastric/GEJ Cancer Space, Alongside Angiogenic, Cytotoxic Agents"